Library / Peptides / Longevity & Anti-Aging / FOXO4
Theoretical · Grade C

FOXO4

Forkhead Box O4
Evidence
Theoretical
Route
Subcutaneous injection (theoretical)
Frequency
Not established
Category
Longevity & Anti-Aging
TL;DR
FOXO4 (Forkhead Box O4) is an endogenous transcription factor, not a therapeutic peptide itself. It belongs to the FOXO family of transcription factors that regulate cellular stress responses, metabolism, and apoptosis.
Part 01 · How it works

Mechanism.

FOXO4 (Forkhead Box O4) is an endogenous transcription factor, not a therapeutic peptide itself. It belongs to the FOXO family of transcription factors that regulate cellular stress responses, metabolism, and apoptosis. In the context of aging research, FOXO4 is notable because it binds to p53 in senescent cells, preventing p53 from triggering apoptosis and thereby keeping senescent 'zombie' cells alive. The therapeutic interest is in disrupting this interaction (see FOXO4-DRI).

Think of p53 as a building demolition expert trying to tear down damaged, non-functional buildings (senescent cells). FOXO4 acts like a security guard that keeps the demolition expert locked in an office, preventing the teardown. The damaged buildings accumulate and cause neighborhood blight (aging).

Mechanism · technical
FOXO4 normally acts as a transcription factor regulating genes involved in oxidative stress resistance, DNA repair, cell cycle arrest, and apoptosis. In senescent cells specifically, FOXO4 accumulates in the nucleus and sequesters p53 in PML (promyelocytic leukemia) nuclear bodies, preventing p53 from activating the mitochondrial apoptosis pathway. This FOXO4-p53 interaction is a key survival mechanism that keeps senescent cells alive.
Part 02 · Dosing & administration

How it's taken.

Values below describe how FOXO4 has been administered in published trials and labeling. Provided for educational purposes only — this is not medical advice and not instructions for self-administration. Consult your healthcare provider before making any health decision.

Standard dose
Not established for humans
Subcutaneous injection (theoretical) · Not established
Duration
Not established

Preclinical research tool only. No human dosing protocols exist. Used in animal models to study senescence. NOT currently viable for clinical use.

Need help with reconstitution?

Use the free peptide calculator for dilution, unit conversion, and injection volume.

Open calculator
Part 03 · Safety

Side effects, rare serious events, who shouldn't.

Reported side effects
FOXO4 is an endogenous protein, not an administered therapeutic. This entry describes the biology; see FOXO4-DRI for the therapeutic peptide designed to interfere with FOXO4's senescence-protective function.
Absolute · do not use
×
Pregnancy or breastfeeding
×
Children under 18
×
Known hypersensitivity to FOXO4 peptide or any component
×
Active wound healing (senescent cell clearance may impair tissue repair in acute phase)
×
Severe thrombocytopenia (senolytic effects may transiently affect platelet-related pathways)
Interactions
Chemotherapy agents
Senolytic peptides may interact with anti-cancer therapy; effects on tumor cell senescence unknown
Moderate
Immunosuppressants
Senescent cell clearance involves immune activation; may conflict with immunosuppressive therapy
Moderate
Anticoagulants (warfarin, DOACs)
Senolytic-induced cell death may transiently increase inflammatory mediators affecting coagulation
Moderate
Labs to monitor
CBC with Differential
Baseline and monthly
Monitor for hematologic changes from senolytic effects
CMP (Comprehensive Metabolic Panel)
Baseline and every 3 months
Liver and kidney function
CRP / ESR
Baseline and monthly
Track inflammatory burden from senescent cell clearance
Part 04 · Research log

Every study we cite.

Each study with its published finding and a plain-language note on limitations or funding.

01
2017
0
Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging
FOXO4-DRI peptide selectively induced apoptosis of senescent cells and restored fitness in aged mice
Landmark preclinical study; single group; no human data
PMID 28340339 ↗
Part 05 · Cost & access

Where you can get it.

Regulatory status
FOXO4 is an endogenous human protein and a research target, not a regulated therapeutic. The related therapeutic peptide FOXO4-DRI is a research compound (see separate entry).
The Peptide Column takes no affiliate commission from any source.
Part 06 · Your appointment

Questions to bring.

01
Is FOXO4 itself used therapeutically, or is the therapeutic target the FOXO4-DRI peptide?
02
What role does cellular senescence play in my specific health concerns?
03
Are there approved senolytic therapies available as alternatives?
04
How is the FOXO family of proteins related to longevity in general?